Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
27/04/2022 21:28
April 27 (Reuters) - Statera Biopharma STAB.O :
* STATERA BIOPHARMA AND IMMUNE THERAPEUTICS INC. ANNOUNCE
STRATEGIC AGREEMENT FOR RIGHTS TO LOW DOSE NALTREXONE
* STATERA BIOPHARMA INC- STATERA WILL RECEIVE AN INITIAL $2
MILLION UPFRONT PAYMENT AND 5% OF ISSUED AND OUTSTANDING STOCK
OF IMMUNE THERAPEUTICS
* STATERA BIOPHARMA INC- TRANSACTION HAS ABILITY TO GENERATE
OVER
$400 MILLION IN NON-DILUTIVE PAYMENTS TO STATERA
Source text for Eikon: ID:nGNX4kJRFG
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc